Estrogen-receptor negative breast cancer

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This study tested the drug pembrolizumab in 71 people with advanced inflammatory or triple-negative breast cancer that had spread or returned. Participants had already responded to chemotherapy. The goal was to see if pembrolizumab could keep the cancer from growing for at least …

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This study tests whether adding the drug panitumumab to standard chemotherapy helps shrink tumors more effectively in people with a rare and aggressive type of breast cancer called triple-negative inflammatory breast cancer. About 42 participants will receive chemotherapy before …

This phase II trial is testing whether giving two chemotherapy drugs, carboplatin and nab-paclitaxel, before surgery can improve outcomes for people with locally advanced or inflammatory triple negative breast cancer. The goal is to see if this approach increases the rate of comp…

This study tests whether adding the experimental drug onvansertib to standard chemotherapy (paclitaxel) can safely shrink tumors in people with triple-negative breast cancer that has spread. About 50 adults with advanced or metastatic disease will receive the combination. The goa…

This phase 1 trial tests a vaccine (p53MVA) that trains the immune system to attack cancer cells with a p53 mutation, given together with the immunotherapy drug pembrolizumab (Keytruda). The study includes 11 people with advanced solid tumors like lung, head and neck, liver, kidn…

This study looks at whether watching an online genetics video, with or without phone counseling from a genetic counselor, can reduce the stress women feel about their cancer risk. It involves 5,200 women aged 30 or older who have had triple-negative breast cancer and still have a…

This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatm…